🇺🇸 C-1-esterase in United States

20 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Adverse Drug Reaction — 2 reports (10%)
  2. Asthma — 2 reports (10%)
  3. Blood Immunoglobulin E Increased — 2 reports (10%)
  4. Chest Discomfort — 2 reports (10%)
  5. Chronic Sinusitis — 2 reports (10%)
  6. Cough — 2 reports (10%)
  7. Dysphonia — 2 reports (10%)
  8. Dyspnoea — 2 reports (10%)
  9. Emotional Distress — 2 reports (10%)
  10. Eosinophilia — 2 reports (10%)

Source database →

C-1-esterase in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is C-1-esterase approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for C-1-esterase in United States?

Penn State University is the originator. The local marketing authorisation holder may differ — check the official source linked above.